Stem Cell Therapeutics Closes $3.1 Million Financing

TORONTO, ONTARIO--(Marketwire - March 15, 2013) -

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S.NEWSWIRE SERVICES

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT"), a life sciences company developing stem cell-related technologies, announced today that it has closed its previously announced prospectus offering of 12,315,000 units ("Units") at a price of $0.25 per Unit for the aggregate gross proceeds of $3,078,750.